Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2 Positive
Interventions: DRUG: paclitaxel, trastuzumab and carboplatin
Sponsor: The Netherlands Cancer Institute